SCHEMBL23326258

SCHEMBL23326258

COc1cc(C2CCCN(C(=O)O)C2)c(OC)cc1C=O

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.45
MAPT P10636 2/20 0.45
HTR2A P28223 3/20 0.44
KDM4E B2RXH2 2/20 0.42
TSHR P16473 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
PROKR1 Q8TCW9 5/20 0.40
MTNR1A P48039 1/20 0.39
MTNR1B P49286 1/20 0.39
LMNA P02545 1/20 0.38
HPGD P15428 1/20 0.38
HIF1A Q16665 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
POLA1 P09884 2/20 0.37
GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28782624 0.85 PDE4B (0.48) ALDH1A1MAPTHTR2A
SCHEMBL23326185 0.80 HTR2A (0.55) ALDH1A1HTR2APROKR1MTNR1AMTNR1B
SCHEMBL23326213 0.78 PTGDR2 (0.57) ALDH1A1KDM4ETSHRPROKR1MTNR1A
SCHEMBL24765632 0.77 ALDH1A1 (0.60) ALDH1A1MAPTHTR2AKDM4ETSHR
SCHEMBL31386247 0.75 PROKR1 (0.48) ALDH1A1MAPTKDM4EPROKR1LMNA
SCHEMBL27223591 0.74 ALDH1A1 (0.41) ALDH1A1MAPTTSHRPROKR1LMNA
SCHEMBL16056155 0.74 ALDH1A1 (0.55) ALDH1A1MAPTHTR2AKDM4ETSHR
SCHEMBL25224504 0.72 PROKR1 (0.47) ALDH1A1PROKR1LMNAHPGDHIF1A
SCHEMBL3962210 0.70 MEN1 (0.47) MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL31690794 0.68 PROKR1 (0.51) ALDH1A1PROKR1LMNAHPGDHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3962601-B1 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION Lophora ApS (DK) 2023-05-31 EP disclosed
US-11642336-B2 5-HT2A agonists for use in treatment of depression Lophora ApS (DK) 2023-05-09 US disclosed
US-11633390-B2 5-HT2A agonists for use in treatment of depression Lophora ApS (DK) 2023-04-25 US disclosed
US-20220062257-A1 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION Lophora ApS (DK) 2022-03-03 US disclosed
US-11246860-B2 5-HT2A agonists for use in treatment of depression Lophora ApS (DK) 2022-02-15 US disclosed
US-20210330658-A1 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION Lophora ApS (DK) 2021-10-28 US disclosed
US-20210137908-A1 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION Lophora ApS (DK) 2021-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210330658-A1 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION HTR2A, HTR2C, HTR5A ALDH1A1 714/4885MAPT 2652/4885HTR2A 1/4885
US-20220062257-A1 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION HTR2A, HTR2C, HTR5A ALDH1A1 714/4885MAPT 2652/4885HTR2A 1/4885
US-11642336-B2 5-HT2A agonists for use in treatment of depression HTR2A, HTR2C, HTR5A ALDH1A1 714/4885MAPT 2652/4885HTR2A 1/4885
US-20210137908-A1 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION HTR2A, HTR2C, HTR5A ALDH1A1 714/4885MAPT 2652/4885HTR2A 1/4885
US-11633390-B2 5-HT2A agonists for use in treatment of depression HTR2A, HTR2C, HTR5A ALDH1A1 714/4885MAPT 2652/4885HTR2A 1/4885
US-11246860-B2 5-HT2A agonists for use in treatment of depression HTR2A, HTR2C, HTR5A ALDH1A1 714/4885MAPT 2652/4885HTR2A 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.